Nonsteroidal antiinflammatory drugs (NSAID) are one of the most commonly used medications worldwide to inhibiting COX activity for the treatment of pain and inflammation. Their nephrotoxicity has been well documented. With the development and clinical implementation of new COX-2 inhibitors, the safety, including the effects on renal function and blood pressure, is attracting increasing attention. In the kidney, COX-2 is constitutively expressed and is highly regulated in response to alterations in intravascular volume. COX-2 metabolites have been implicated in mediation of renin release, regulation of sodium excretion and maintenance of renal blood flow. Similar to conventional NSAIDs, inhibition of COX-2 may cause edema and modest elevations in blood pressure in a minority of subjects. COX-2 inhibitors may also exacerbate preexisting hypertension or interfere with other antihypertensive drugs. Occasional acute renal failure has also been reported. Caution should be taken when COX-2 inhibitors are prescribed, especially in highrisk patients (including elderly and patients with volume depletion). Recently, agents with combined lipooxygenase/COX inhibition and agents that combine NSAIDs with a nitric oxide (NO) donor have been reported to reduce adverse renal effects.
Keywords: cox-2, cox-1, nsaid, hypertension, renin, sodium excretion, renal function, kidney
Beneficial Effects of Selective Vitamin D Receptor Activation by Paricalcitol in Chronic Kidney Disease
Current Drug Targets Oral Antidiabetic Agents: Anti-Atherosclerotic Properties Beyond Glucose Lowering?
Current Pharmaceutical Design Does Handle Region Peptide Provide Benefits in Chronic Kidney Disease?
Current Hypertension Reviews An Evaluation of the Clinical Therapeutic Effect of Lixisenatide in Type 2 Diabetes Patients: A Systematic Literature Review
Current Diabetes Reviews Synthesis and Endothelin Receptors Binding Affinity of New 1,3,5- Substituted Pyrrole-2-Carboxylic Acid Derivatives
Medicinal Chemistry CACNB2: An Emerging Pharmacological Target for Hypertension, Heart Failure, Arrhythmia and Mental Disorders
Current Molecular Pharmacology Cardioprotection with Sildenafil: Implications for Clinical Practice
Current Medicinal Chemistry A Review on the Risk of Myocardial Infarction Associated with the NSAID Diclofenac
Cardiovascular & Hematological Disorders-Drug Targets The Etiology of Hypertension in the Metabolic Syndrome Part Three: The Regulation and Dysregulation of Blood Pressure
Current Vascular Pharmacology Role of the Autonomic Nervous System in the Endothelial Dysfunction of the Metabolic Syndrome
Current Hypertension Reviews Pomegranate Consumption and Blood Pressure: A Review
Current Pharmaceutical Design Circulating and Vascular Bioactive Factors During Hypertension in Pregnancy
Current Bioactive Compounds Adiponectin - A Novel Anti-Atherogenic Factor in the Metabolic Syndrome: Mechanisms of Action and Therapeutic Potential
Vascular Disease Prevention Metabolic Syndrome: Clinical Features Leading to Therapeutic Strategies
Vascular Disease Prevention Molecular Mechanisms of Neuronal Histamine and its Receptors in Obesity
Current Molecular Pharmacology Arylpiperazines with Affinity Toward a1-Adrenergic Receptors
Current Medicinal Chemistry Mechanisms Underlying Beneficial Health Effects of Tea Catechins to Improve Insulin Resistance and Endothelial Dysfunction
Endocrine, Metabolic & Immune Disorders - Drug Targets Lenticulostriate Artery and Lenticulostriate-artery Neural Complex: New Concept for Intracerebral Hemorrhage
Current Pharmaceutical Design A Newly Found Gasotransmitter, Hydrogen Sulfide, in the Pathogenesis of Hypertension and Other Cardiovascular Diseases
Current Hypertension Reviews Gender Differences in the Effects of Angiotensin Receptor Blockers on Cardiovascular Disease
Current Pharmaceutical Design